BioCentury
ARTICLE | Clinical News

AP611074: Phase IIa data

February 3, 2014 8:00 AM UTC

A double-blind, placebo-controlled, Phase IIa trial in 24 condyloma patients showed that twice-daily AP611074 5% topical gel for 6 weeks was safe with no patient drop-outs or treatment interruptions r...